抗体药物偶联物相关眼毒性的研究进展  

Research progress of drug-induced ocular toxicity of antibody-drug conjugate

作　　者：夏凡[1] 张晶晶[1] 杭永付[1] 朱建国[1] 缪丽燕[1] Fan XIA;Jing-Jing ZHANG;Yong-Fu HANG;Jian-Guo ZHU;Li-Yan MIAO(Department of Pharmacy,the First Affiliated Hospital of Soochow University,Suzhou 215006,Jiangsu Province,China)

机构地区：[1]苏州大学附属第一医院药学部,江苏苏州215006

出　　处：《药物流行病学杂志》2023年第9期985-990,共6页Chinese Journal of Pharmacoepidemiology

基　　金：中国研究型医院学会药物评价专委会临床重点药品的使用监测和评价研究专项课题(Y2022FH-YWPJ01-102);白求恩·求索-药学科研能力建设项目(Z04JKM2021005)。

摘　　要：抗体药物偶联物(ADC)是一类具有独特作用机制的抗肿瘤新药,目前已成为肿瘤领域的焦点和热点。在ADC药物相关临床研究中,眼毒性是其特征性不良事件之一,虽然大多数眼部不良事件程度轻微且可逆,但部分患者的治疗进程可能受到影响。因此美国食品药品管理局要求在该类药物说明书中增加眼毒性的黑框警示。本研究对ADC药物眼毒性的流行病学、临床表现、发生机制和防治策略进行综述,旨在提高临床医务人员对ADC药物相关眼毒性的认识,为临床ADC药物的个体化风险评估、早期诊断和医学管理提供参考。Antibody-drug conjugate(ADC)drugs is a kind of antitumor drug with the unique mechanism and have become the focus and hotspots in the field of cancer.Ocular toxicity is one of the characteristic adverse events of ADC drugs in clinical studies.Although most ocular events are mild and reversible,the course of treatment may be affected in some patients.Therefore,the U.S.Food and Drug Administration requires that a black box warning of ocular toxicity to be added into the instruction of such drugs.In this study,we summarized the epidemiology,clinical manifestations,potential mechanism and prevention and treatment strategies in order to increase the awareness about ocular toxicity associated with ADC for clinicians,and provide references for individualized risk assessment,early diagnosis and medical management of ADC drugs.

关 键 词：抗体药物偶联物 眼毒性 黑框警告 药品不良事件 

分 类 号：R969[医药卫生—药理学]